BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 37992548)

  • 1. Impact of postoperative morbidity on outcomes in patients with advanced epithelial ovarian cancer undergoing intestinal surgery at the time of primary or interval cytoreductive surgery: A Memorial Sloan Kettering Cancer Center Team Ovary study.
    Praiss AM; Hirani R; Zhou Q; Iasonos A; Sonoda Y; Abu-Rustum NR; Leitao MM; Long Roche K; Broach V; Gardner GJ; Chi DS; Zivanovic O
    Gynecol Oncol; 2023 Dec; 179():169-179. PubMed ID: 37992548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncologic outcomes after splenectomy during initial cytoreductive surgery in advanced epithelial ovarian cancer: a nationwide population-based cohort study.
    Said SA; van der Aa MA; Veldmate G; de Hullu JA; van Altena AM
    Acta Obstet Gynecol Scand; 2022 Jan; 101(1):56-67. PubMed ID: 34719790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ultra-radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer.
    Hiu S; Bryant A; Gajjar K; Kunonga PT; Naik R
    Cochrane Database Syst Rev; 2022 Aug; 8(8):CD007697. PubMed ID: 36041232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy for Stage III Epithelial Ovarian Cancer.
    Lei Z; Wang Y; Wang J; Wang K; Tian J; Zhao Y; Chen L; Wang J; Luo J; Jia M; Tang H; He Q; Liao Q; Yang X; Guan T; Wang L; Cui S;
    JAMA Netw Open; 2020 Aug; 3(8):e2013940. PubMed ID: 32840622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. National trends in bowel and upper abdominal procedures in ovarian cancer surgery.
    Dottino JA; He W; Sun CC; Zhao H; Fu S; Rauh-Hain JA; Suidan RS; Lu KH; Giordano SH; Meyer LA
    Int J Gynecol Cancer; 2020 Aug; 30(8):1195-1202. PubMed ID: 32616627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperthermic Intraperitoneal Chemotherapy After Interval Cytoreductive Surgery for Patients With Advanced-Stage Ovarian Cancer Who Had Received Neoadjuvant Chemotherapy.
    Lee JY; Lee YJ; Son JH; Kim S; Choi MC; Suh DH; Song JY; Hong DG; Kim MK; Kim JH; Chang SJ
    JAMA Surg; 2023 Nov; 158(11):1133-1140. PubMed ID: 37672264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival outcomes of acute normovolemic hemodilution in patients undergoing primary debulking surgery for advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center Team Ovary study.
    Boerner T; Tanner E; Filippova O; Zhou QC; Iasonos A; Tew WP; O'Cearbhaill RE; Grisham RN; Gardner GJ; Sonoda Y; Abu-Rustum NR; Zivanovic O; Long Roche K; Afonso AM; Fischer M; Chi DS
    Gynecol Oncol; 2021 Jan; 160(1):51-55. PubMed ID: 33213899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive and Prognostic Implication of Bowel Resections During Primary Cytoreductive Surgery in Advanced Epithelial Ovarian Cancer.
    Bartl T; Schwameis R; Stift A; Bachleitner-Hofmann T; Reinthaller A; Grimm C; Polterauer S
    Int J Gynecol Cancer; 2018 Nov; 28(9):1664-1671. PubMed ID: 30371563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical characteristics and outcomes after bowel surgery and ostomy formation at the time of debulking surgery for advanced-stage epithelial ovarian carcinoma.
    Gockley AA; Fiascone S; Hicks Courant K; Pepin K; Del Carmen M; Clark RM; Goldberg J; Horowitz N; Berkowitz R; Worley M
    Int J Gynecol Cancer; 2019 Mar; 29(3):585-592. PubMed ID: 30833444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of morbidity and survival between primary and interval cytoreductive surgery in patients after modified posterior pelvic exenteration for advanced ovarian cancer.
    Revaux A; Rouzier R; Ballester M; Selle F; Daraï E; Chéreau E
    Int J Gynecol Cancer; 2012 Oct; 22(8):1349-54. PubMed ID: 22954783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment outcomes and predictive factors in patients ≥70 years old with advanced ovarian cancer.
    Piedimonte S; Bernardini MQ; May T; Cybulska P; Ferguson SE; Laframboise S; Bouchard-Fortier G; Avery L; Hogen L
    J Surg Oncol; 2022 Mar; 125(4):736-746. PubMed ID: 34786711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anastomotic leak following interval debulking surgery with or without hyperthermic intraperitoneal chemotherapy in women with advanced epithelial ovarian Cancer.
    Gruner M; Chambers LM; Yao M; Chichura A; Morton M; Costales AB; Horowitz M; Rose PG; Debernardo R; Michener CM
    Gynecol Oncol; 2021 Sep; 162(3):645-651. PubMed ID: 34247768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does sites of recurrence impact survival in secondary cytoreduction surgery for recurrent epithelial ovarian cancer?
    Kumar S; Srinivasan A; Phillips A; Madhupriya R; Pascoe J; Nevin J; Elattar A; Balega J; Cummins C; Sundar S; Kehoe ST; Singh K
    J Obstet Gynaecol; 2020 Aug; 40(6):849-855. PubMed ID: 31933417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer.
    Coleridge SL; Bryant A; Kehoe S; Morrison J
    Cochrane Database Syst Rev; 2021 Jul; 7(7):CD005343. PubMed ID: 34328210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. When Less Is More: Minimally Invasive Surgery Compared with Laparotomy for Interval Debulking After Neoadjuvant Chemotherapy in Women with Advanced Ovarian Cancer.
    Brown J; Drury L; Crane EK; Anderson WE; Tait DL; Higgins RV; Naumann RW
    J Minim Invasive Gynecol; 2019; 26(5):902-909. PubMed ID: 30240899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncologic outcomes and morbidity following heated intraperitoneal chemotherapy at cytoreductive surgery for primary epithelial ovarian cancer: A systematic review and meta-analysis.
    Bouchard-Fortier G; Cusimano MC; Fazelzad R; Sajewycz K; Lu L; Espin-Garcia O; May T; Bouchard-Fortier A; Ferguson SE
    Gynecol Oncol; 2020 Jul; 158(1):218-228. PubMed ID: 32387131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy.
    Maheshwari A; Kumar N; Gupta S; Rekhi B; Shylasree TS; Dusane R; Bajpai J; Ghosh J; Gulia S; Deodhar K; Menon S; Popat P; Sable N; Thakur M; Kerkar R
    Indian J Cancer; 2018; 55(1):50-54. PubMed ID: 30147093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncologic outcomes in patients undergoing maximal or optimal cytoreductive surgery for Stage 3C serous ovarian, tubal or peritoneal carcinomas.
    Gurkan D; Ceren Akin A; Sahin H; Aytac Tohma Y; Sahin EA; Gunakan E; Iflazoglu N; Nihan Haberal A; Ayhan A
    J Obstet Gynaecol; 2020 May; 40(4):551-557. PubMed ID: 31482736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interval debulking surgery is not worth the wait: a National Cancer Database study comparing primary cytoreductive surgery versus neoadjuvant chemotherapy.
    Lyons YA; Reyes HD; McDonald ME; Newtson A; Devor E; Bender DP; Goodheart MJ; Gonzalez Bosquet J
    Int J Gynecol Cancer; 2020 Jun; 30(6):845-852. PubMed ID: 32341114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leave it in the past - primary treatment modality for high-grade epithelial ovarian cancer is not associated with secondary cytoreduction outcomes: A Memorial Sloan Kettering Cancer Center Team Ovary study.
    Sia TY; Manning-Geist BL; Ehmann S; Lavery JA; Luardo C; Praiss A; Iasonos A; Sonoda Y; Grisham RN; Liu YL; Broach V; Zivanovic O; Long Roche K; Gardner GJ; Chi DS
    Gynecol Oncol; 2023 Sep; 176():69-75. PubMed ID: 37454565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.